5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Extracellular vesicles isolated from human renal cell carcinoma tissues disrupt vascular endothelial cell morphology via azurocidin.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cancer-associated extracellular vesicles (EVs) are intimately involved in establishment of tumor microenvironment and occurrence of metastasis. However, previous studies have mainly relied on experiments with cultured cell lines or mouse models, making it difficult to gain a full understanding of EV functions in human body. Hence, we extracted EVs directly from surgically resected viable clear cell renal cell carcinoma (ccRCC) tissues and adjacent normal renal tissues (n = 20). Quantitative LC/MS analysis identified 3,871 tissue-exudative EV (Te-EV) proteins, among which azurocidin (AZU1) was highly enriched in tumor Te-EVs (p = 2.85 × 10-3 , fold-change = 31.59). Importantly, AZU1 content was also significantly higher in serum EVs from ccRCC patients compared to those from healthy donors. We further found that ccRCC-derived EVs had AZU1-dependent membrane permeabilizing activity for the vascular endothelial cell layer. Thus Te-EVs should be ideal resource for investigation of physiological EV functions.

          Related collections

          Author and article information

          Journal
          Int. J. Cancer
          International journal of cancer
          Wiley
          1097-0215
          0020-7136
          February 01 2018
          : 142
          : 3
          Affiliations
          [1 ] Laboratory of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
          [2 ] Department of Therapeutic Urologic Oncology, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
          [3 ] Department of Urology, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
          [4 ] Project for Personalized Cancer Medicine, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
          Article
          10.1002/ijc.31080
          28975613
          b958c79f-cf95-46a4-8650-d36a7edec87f
          History

          azurocidin (AZU1),clear cell renal cell carcinoma (ccRCC),tissue-exudative extracellular vesicles (Te-EVs)

          Comments

          Comment on this article